Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful ...

Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...

Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron ...

Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual ...

Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and ...

US biotech Nektar Therapeutics has announced results of its Phase II proof-of-concept study of NKTR-255 as an adjuvant ...

BeiGene has sought to underscore its leading position in the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL ...

Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk ...

MaaT Pharma reports Phase II results for MaaT013 in acute graft-versus-host disease, showing significant survival benefits ...

Gilead Sciences presents five-year Phase II ZUMA-5 trial results for Yescarta in relapsed non-Hodgkin lymphomas, showing a 90 ...

Johnson & Johnson’s Carvykti demonstrates strong Phase III CARTITUDE-4 results in multiple myeloma, achieving 89% MRD ...

Vivoryon Therapeutics announces Phase II trial results for varoglutamstat, showing no efficacy in cognitive endpoints but ...